Melanotan II Half-Life: How Long It Stays in Your System
How long Melanotan II stays in the body, how that shapes dosing frequency, and what is known about drug testing.
- Half-life
- Not found
- No published half-life found (PubMed search, 2 Oct 2026)
- Dosing interval
- Varies by study
- as used in studies
- WADA
- Unclear
- Not named on the 2026 list
- Detection window
- Not found
- None reported as of 2 Oct 2026
Melanotan II half-life
Half-life: no published half-life found (PubMed search, 2 Oct 2026). A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray), so we report it per route with the study it came from.
What half-life means
Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.
- A long half-life lets a drug be dosed less often, for example once a week.
- A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
- Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.
What it means for dosing frequency
Dosing intervals used in published studies of Melanotan II:
- daily Monday to Friday, subcutaneous (Human controlled trial; Life sciences 1996, PMID 8637402)
- 10 min before each paced mating test, intravenous (Animal · rat; Pharmacology, biochemistry, and behavior 2006, PMID 17113634)
Changing the interval changes how much drug builds up between doses, so it is not a free choice.
Drug tests and sport
WADA status unclearMelanotan II: This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.
Anti-doping labs use tests built for specific substances. Whether a given test detects Melanotan II, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026).
The rat studies of MT-II
In rats given MT-II intravenously, plasma concentrations showed a biphasic disposition, and HPLC and bioassay profiles were essentially superimposable.[9]
The authors note that even one aberrant data point in the beta phase can significantly influence t1/2 beta when only a few points are available.[9]
A later LC/MS/MS method for MT-II in rat plasma reached a limit of quantitation of 5 ng/mL.[10]
Do not mix it up with melanotan-I
A human trial of melanotan-I, a different peptide, found subcutaneous beta-phase half-lives of 0.8 to 1.7 h.[11]
Drugs@FDA returns no melanotan product, so there is no label with an MT-II half-life.[12]
Drug-testing context
WADA does not name melanotan II; the S0 catch-all is the only clause that could reach it.[2]
Common questions
How long does Melanotan II stay in your system?
We found no published half-life for Melanotan II (PubMed search, 2 Oct 2026). As a rule, most of a dose is cleared after about four to five half-lives.
What is the half-life of Melanotan II?
No published half-life was found in our PubMed search, 2 Oct 2026. We add one with its source and route if a study reports it.
Is Melanotan II on the WADA prohibited list?
It is unclear. Melanotan II: This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.
What is the half-life of melanotan 2?
No human value is cached. In rats MT-II showed a biphasic plasma profile, and the authors note that a single aberrant data point can shift the beta-phase half-life estimate.[9]
What is the half-life of melanotan?
It depends which peptide is meant: melanotan-I had a subcutaneous beta-phase of 0.8 to 1.7 h in people.[11]
More on Melanotan II
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.Life sciences · 1996PMID 8637402Accessed 2 Oct 2026
- 4The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat.Pharmacology, biochemistry, and behavior · 2006PMID 17113634Accessed 2 Oct 2026
- 5PubMed search: "melanotan II"[tiab] OR "melanotan 2"[tiab] (198 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: ("melanotan II"[tiab] OR melanotan[tiab]) AND humans[mh] (82 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("melanotan II"[tiab] OR "melanotan 2"[tiab] OR melanotan[ti]) AND (case[tiab] OR naevi[tiab] OR nevi[tiab] OR melanoma[tiab] OR adverse[tiab] OR priapism[tiab] OR tanning[tiab] OR sunless[tiab]) AND humans[mh] (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("melanotan II"[tiab] OR "melanotan 2"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats.Biopharmaceutics & drug disposition · 1994PMID 7981427Accessed 2 Oct 2026
- 10Determination of melanotan-II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration.Rapid communications in mass spectrometry : RCM · 2002PMID 12415547Accessed 2 Oct 2026
- 11Skin pigmentation and pharmacokinetics of melanotan-I in humans.Biopharmaceutics & drug disposition · 1997PMID 9113347Accessed 2 Oct 2026
- 12Drugs@FDA (openFDA) search: active ingredient "melanotan"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.